Hishima Tsunekazu, Oyaizu Naoki, Fujii Takeshi, Tachikawa Natsuo, Ajisawa Atsushi, Negishi Masayoshi, Nakamura Tetsuya, Iwamoto Aikichi, Hayashi Yukiko, Matsubara Daisuke, Sasao Yuki, Kimura Satoshi, Kikuchi Yoshimi, Teruya Katsuji, Yasuoka Akira, Oka Shinichi, Saito Kiyoshi, Mori Shigeo, Funata Nobuaki, Sata Tetsutaro, Katano Harutaka
Department of Pathology, Tokyo Metropolitan Komagome Hospital, Honkomagome 3-18-22, Bunkyo-ku, Tokyo 113-8677, Japan.
Microbes Infect. 2006 Apr;8(5):1301-7. doi: 10.1016/j.micinf.2005.12.012. Epub 2006 Mar 15.
Recent introduction of highly active antiretroviral therapy (HAART) is reported to have reduced the incidence of lymphoma among HIV-infected individuals. A clinicopathological study was performed on 86 AIDS-related lymphoma patients who were treated in Tokyo area from 1987 to 2005. The incidence of lymphoma detected by autopsy was 27% (53 cases/198 autopsies). Diffuse large B cell lymphoma was the most predominant histological subtype throughout the period (78%). Burkitt's lymphoma (BL) increased from 2% in the pre-HAART era (before end-1997) to 13% in the HAART era, whereas incidence of BL did not vary between HAART users and non-users. Epstein-Barr virus (EBV)-positive lymphoma decreased from 88% in the pre-HAART era to 58% in the HAART era, but did not differ significantly between HAART users (73%) and non-users (74%). Nodal involvement of lymphoma increased from 14% in the pre-HAART era to 50% in the HAART era; however, central nervous system involvement decreased from 62 to 38%. Kaposi's sarcoma-associated herpesvirus infection was rare (4%) among all cases. These data suggest that HAART might play a partial role in these changes, and the alteration in immunological backgrounds, such as EBV prevalence, is suggested as another leading cause of these changes in Japanese AIDS-related lymphoma.
据报道，近期引入的高效抗逆转录病毒疗法（HAART）降低了HIV感染者中淋巴瘤的发病率。对1987年至2005年在东京地区接受治疗的86例艾滋病相关淋巴瘤患者进行了临床病理研究。尸检检测到的淋巴瘤发病率为27%（53例/198例尸检）。弥漫性大B细胞淋巴瘤在整个时期都是最主要的组织学亚型（78%）。伯基特淋巴瘤（BL）在HAART时代前（1997年底之前）为2%，在HAART时代增至13%，而BL在HAART使用者和非使用者之间的发病率没有差异。爱泼斯坦-巴尔病毒（EBV）阳性淋巴瘤在HAART时代前为88%，在HAART时代降至58%，但在HAART使用者（73%）和非使用者（74%）之间没有显著差异。淋巴瘤的淋巴结受累从HAART时代前的14%增至HAART时代的50%；然而，中枢神经系统受累从62%降至38%。卡波西肉瘤相关疱疹病毒感染在所有病例中很少见（4%）。这些数据表明，HAART可能在这些变化中起部分作用，免疫背景的改变，如EBV流行率，被认为是日本艾滋病相关淋巴瘤这些变化的另一个主要原因。
